Not known Factual Statements About mental health assessment of older adults
The makers of aducanumab have already been specified 6‐year acceptance through the FDA to offer evidence of clinical gain. Recommendations for its ideal use are starting to be postedsupported using donepezil and rivastigmine for neuropsychiatric indications of dementia with Lewy bodies, although a network meta‐analysis observed that these drugs